We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

41 hedge funds and large institutions have $41.6M invested in Axsome Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

32.21% more ownership

Funds ownership: 0% → 32.21% (+32%)

14% more funds holding

Funds holding: 36 → 41 (+5)

16% less capital invested

Capital invested by funds: $49.4M → $41.6M (-$7.8M)

Holders
41
Holders Change
+5
Holders Change %
+13.89%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
14
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$596K
2
BFA
BlackRock Fund Advisors
California
+$399K
3
Morgan Stanley
Morgan Stanley
New York
+$199K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$130K
5
BIT
BlackRock Institutional Trust
California
+$89.1K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.19M
2
LOAMU
Lombard Odier Asset Management (USA)
New York
-$548K
3
Citadel Advisors
Citadel Advisors
Florida
-$104K
4
BA
BlackRock Advisors
Delaware
-$4.35K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$3.74K
Name Holding Trade Value Shares
Change 		Change in
Stake
NFA
26
Nationwide Fund Advisors
Ohio
$44K – – –
AIG
27
American International Group
New York
$43K -$119 -17 -0.3%
BA
28
BlackRock Advisors
Delaware
$26K -$4.35K -619 -14%
SO
29
STRS Ohio
Ohio
$24K – – –
Citigroup
30
Citigroup
New York
$23K +$17.8K +2,533 +278%
Wells Fargo
31
Wells Fargo
California
$16K – – –
UBS Group
32
UBS Group
Switzerland
$12K +$12.3K +1,750 New
Bank of America
33
Bank of America
North Carolina
$10K +$7.22K +1,028 +206%
Legal & General Group
34
Legal & General Group
United Kingdom
$8K +$8.13K +1,158 New
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$5K +$5.33K +759 New
Manulife (Manufacturers Life Insurance)
36
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4K – – –
MAM
37
Meeder Asset Management
Ohio
$4K +$4.21K +600 New
BlackRock
38
BlackRock
New York
$3K – – –
LTFS
39
Ladenburg Thalmann Financial Services
Florida
$3K – – –
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$1.5K -$3.74K -533 -71%
Barclays
41
Barclays
United Kingdom
$1K – – –
Citadel Advisors
42
Citadel Advisors
Florida
– -$104K -13,171 Closed
1
2

AXSM Hedge Fund Activity: Q4 2016 in Review

41 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2016, worth a combined $41.6M — down 16% from $49.4M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AXSM positions and 1 closed out — a net gain of 5 holders — while 14 added to existing stakes and 6 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $596K. The largest seller was Fidelity Investments, cutting an estimated $2.19M.

  • 41 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2016, up from 36 in Q3 2016.
  • Funds reported $41.6M of Axsome Therapeutics stock for Q4 2016, down 16% quarter-over-quarter.
  • 6 funds opened new Axsome Therapeutics positions in Q4 2016 and 1 closed out, a net change of +5 holders.
  • The largest Axsome Therapeutics buyer in Q4 2016 was Millennium Management, an estimated $596K added.
  • The largest Axsome Therapeutics seller in Q4 2016 was Fidelity Investments, an estimated $2.19M sold.

Based on aggregated 13F filings for Q4 2016.